Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement

Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., Scholvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., Bossink, A., Duarte, R., Erkens, C., Clark, J., Migliori, G. B. and Lange, C. (2010) Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. European Respiratory Journal, 36 5: 1185-1206. doi:10.1183/09031936.00028510


Author Solovic, I.
Sester, M.
Gomez-Reino, J. J.
Rieder, H. L.
Ehlers, S.
Milburn, H. J.
Kampmann, B.
Hellmich, B.
Groves, R.
Schreiber, S.
Wallis, R. S.
Sotgiu, G.
Scholvinck, E. H.
Goletti, D.
Zellweger, J. P.
Diel, R.
Carmona, L.
Bartalesi, F.
Ravn, P.
Bossink, A.
Duarte, R.
Erkens, C.
Clark, J.
Migliori, G. B.
Lange, C.
Title Series "update on tuberculosis" edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement
Journal name European Respiratory Journal   Check publisher's open access policy
ISSN 0903-1936
1399-3003
Publication date 2010-11-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1183/09031936.00028510
Volume 36
Issue 5
Start page 1185
End page 1206
Total pages 22
Place of publication Lausanne, Switzerland
Publisher European Respiratory Society
Language eng
Abstract Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-c release assays or, as an alternative in individuals without a history of bacille Calmette-Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis. Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistent M. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB. This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy. Copyright
Keyword Interferon-γ release assay
Tuberculin skin test
Tuberculosis
Tumour necrosis factor
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 193 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 222 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 10 Feb 2016, 20:44:43 EST by Ms Kate Rowe on behalf of Learning and Research Services (UQ Library)